Skip to main content

and
  1. Article

    Open Access

    Prescribers’ satisfaction with delivering medications for opioid use disorder

    Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescribe...

    Hannah K. Knudsen, Randy Brown in Substance Abuse Treatment, Prevention, and… (2021)

  2. Article

    Open Access

    Physicians’ satisfaction with providing buprenorphine treatment

    Buprenorphine is a critically important treatment for addressing the opioid epidemic, but there are virtually no studies of physicians’ job satisfaction with providing buprenorphine. Physicians’ job satisfacti...

    Hannah K. Knudsen, Randy Brown, Nora Jacobson in Addiction Science & Clinical Practice (2019)

  3. Article

    Open Access

    Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio

    Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial influence over the adoption and use of this medication to enhance recovery. Their views could provide in...

    Todd Molfenter, Carol Sherbeck, Mark Zehner in Substance Abuse Treatment, Prevention, and… (2015)

  4. No Access

    Article

    Cationic Lipid-Coated Gold Nanoparticles as Efficient and Non-Cytotoxic Intracellular siRNA Delivery Vehicles

    Cationic lipid-coated gold nanoparticles were developed for efficient intracellular delivery of therapeutic siRNA.

    Won Ho Kong, Ki Hyun Bae, Sung Duk Jo, Jee Seon Kim in Pharmaceutical Research (2012)